Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response
Adoptive T cell therapy has emerged as a powerful strategy to treat human cancers especially haematological malignancies. Extension of these therapies to solid cancers remains a significant challenge especially in the context of defining immunological correlates of clinical responses. Here we descri...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-02-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2016.1273311 |
id |
doaj-0d074c6887494e51b57d37814a7a23d1 |
---|---|
record_format |
Article |
spelling |
doaj-0d074c6887494e51b57d37814a7a23d12020-11-25T03:15:03ZengTaylor & Francis GroupOncoImmunology2162-402X2017-02-016210.1080/2162402X.2016.12733111273311Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical responseCorey Smith0Victor Lee1Andrea Schuessler2Leone Beagley3Sweera Rehan4Janice Tsang5Vivian Li6Randal Tiu7David Smith8Michelle A. Neller9Katherine K. Matthews10Emma Gostick11David A. Price12Jacqueline Burrows13Glen M. Boyle14Daniel Chua15Benedict Panizza16Sandro V. Porceddu17John Nicholls18Dora Kwong19Rajiv Khanna20QIMR Berghofer Medical Research InstituteQueen Mary Hospital, The University of Hong KongQIMR Berghofer Medical Research InstituteQIMR Berghofer Medical Research InstituteQIMR Berghofer Medical Research InstituteQueen Mary Hospital, The University of Hong KongQueen Mary Hospital, The University of Hong KongQueen Mary Hospital, The University of Hong KongQIMR Berghofer Medical Research InstituteQIMR Berghofer Medical Research InstituteQIMR Berghofer Medical Research InstituteInstitute of Infection and Immunity, Cardiff University School of MedicineInstitute of Infection and Immunity, Cardiff University School of MedicineQIMR Berghofer Medical Research InstituteQIMR Berghofer Medical Research InstituteComprehensive Oncology Centre, Hong Kong Sanatorium HospitalThe Princess Alexandra Hospital, University of QueenslandThe Princess Alexandra Hospital, University of QueenslandQueen Mary Hospital, The University of Hong KongQueen Mary Hospital, The University of Hong KongQIMR Berghofer Medical Research InstituteAdoptive T cell therapy has emerged as a powerful strategy to treat human cancers especially haematological malignancies. Extension of these therapies to solid cancers remains a significant challenge especially in the context of defining immunological correlates of clinical responses. Here we describe results from a clinical study investigating autologous Epstein-Barr virus (EBV)-specific T cells generated using a novel AdE1-LMPpoly vector to treat patients with nasopharyngeal carcinoma (NPC) either pre-emptively in at-risk patients with no or minimal residual disease (N/MRD) or therapeutically in patients with active recurrent/metastatic disease (ARMD). Tolerability, safety and efficacy, including progression-free survival (PFS) and overall survival (OS), were evaluated following adoptive T-cell immunotherapy. Twenty-nine patients, including 20 with ARMD and nine with N/MRD, successfully completed T-cell therapy. After a median follow-up of 18.5 months, the median PFS was 5.5 months (95% CI 2.1 to 9.0 months) and the median OS was 38.1 months (95% CI 17.2 months to not reached). Post-immunotherapy analyses revealed that disease stabilization in ARMD patients was significantly associated with the functional and phenotypic composition of in vitro-expanded T cell immunotherapy. These included a higher proportion of effector CD8+ T-cells and an increased number of EBV-specific T-cells with broader antigen specificity. These observations indicate that adoptive immunotherapy with AdE1-LMPpoly-expanded T cells stabilizes relapsed, refractory NPC without significant toxicity. Promising clinical outcomes in N/MRD patients further suggest a potential role for this approach as a consolidation treatment following first-line chemotherapy.http://dx.doi.org/10.1080/2162402X.2016.1273311adoptive immunotherapyepstein-barr virust cellssafetynasopharyngeal carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Corey Smith Victor Lee Andrea Schuessler Leone Beagley Sweera Rehan Janice Tsang Vivian Li Randal Tiu David Smith Michelle A. Neller Katherine K. Matthews Emma Gostick David A. Price Jacqueline Burrows Glen M. Boyle Daniel Chua Benedict Panizza Sandro V. Porceddu John Nicholls Dora Kwong Rajiv Khanna |
spellingShingle |
Corey Smith Victor Lee Andrea Schuessler Leone Beagley Sweera Rehan Janice Tsang Vivian Li Randal Tiu David Smith Michelle A. Neller Katherine K. Matthews Emma Gostick David A. Price Jacqueline Burrows Glen M. Boyle Daniel Chua Benedict Panizza Sandro V. Porceddu John Nicholls Dora Kwong Rajiv Khanna Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response OncoImmunology adoptive immunotherapy epstein-barr virus t cells safety nasopharyngeal carcinoma |
author_facet |
Corey Smith Victor Lee Andrea Schuessler Leone Beagley Sweera Rehan Janice Tsang Vivian Li Randal Tiu David Smith Michelle A. Neller Katherine K. Matthews Emma Gostick David A. Price Jacqueline Burrows Glen M. Boyle Daniel Chua Benedict Panizza Sandro V. Porceddu John Nicholls Dora Kwong Rajiv Khanna |
author_sort |
Corey Smith |
title |
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response |
title_short |
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response |
title_full |
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response |
title_fullStr |
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response |
title_full_unstemmed |
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response |
title_sort |
pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of t cells impact on clinical response |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2017-02-01 |
description |
Adoptive T cell therapy has emerged as a powerful strategy to treat human cancers especially haematological malignancies. Extension of these therapies to solid cancers remains a significant challenge especially in the context of defining immunological correlates of clinical responses. Here we describe results from a clinical study investigating autologous Epstein-Barr virus (EBV)-specific T cells generated using a novel AdE1-LMPpoly vector to treat patients with nasopharyngeal carcinoma (NPC) either pre-emptively in at-risk patients with no or minimal residual disease (N/MRD) or therapeutically in patients with active recurrent/metastatic disease (ARMD). Tolerability, safety and efficacy, including progression-free survival (PFS) and overall survival (OS), were evaluated following adoptive T-cell immunotherapy. Twenty-nine patients, including 20 with ARMD and nine with N/MRD, successfully completed T-cell therapy. After a median follow-up of 18.5 months, the median PFS was 5.5 months (95% CI 2.1 to 9.0 months) and the median OS was 38.1 months (95% CI 17.2 months to not reached). Post-immunotherapy analyses revealed that disease stabilization in ARMD patients was significantly associated with the functional and phenotypic composition of in vitro-expanded T cell immunotherapy. These included a higher proportion of effector CD8+ T-cells and an increased number of EBV-specific T-cells with broader antigen specificity. These observations indicate that adoptive immunotherapy with AdE1-LMPpoly-expanded T cells stabilizes relapsed, refractory NPC without significant toxicity. Promising clinical outcomes in N/MRD patients further suggest a potential role for this approach as a consolidation treatment following first-line chemotherapy. |
topic |
adoptive immunotherapy epstein-barr virus t cells safety nasopharyngeal carcinoma |
url |
http://dx.doi.org/10.1080/2162402X.2016.1273311 |
work_keys_str_mv |
AT coreysmith preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT victorlee preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT andreaschuessler preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT leonebeagley preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT sweerarehan preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT janicetsang preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT vivianli preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT randaltiu preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT davidsmith preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT michelleaneller preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT katherinekmatthews preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT emmagostick preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT davidaprice preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT jacquelineburrows preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT glenmboyle preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT danielchua preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT benedictpanizza preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT sandrovporceddu preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT johnnicholls preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT dorakwong preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse AT rajivkhanna preemptiveandtherapeuticadoptiveimmunotherapyfornasopharyngealcarcinomaphenotypeandeffectorfunctionoftcellsimpactonclinicalresponse |
_version_ |
1724640808048525312 |